Multimodal diagnostic approach and surgical management of suspected malignant gallbladder tumor: A case report
DOI: https://doi.org/10.33024/minh.v9i3.3001
Case Report Cholecystectomy Gallbladder Cancer Gallbladder Tumor Hepatobiliary Surgery
Abstract
Background: Gallbladder cancer is the most common tumor of the biliary tract and is recognized as one of the most aggressive gastrointestinal malignancies with a poor prognosis. Most cases are diagnosed at an advanced stage, which limits therapeutic options. According to data from the International Agency for Research on Cancer through the Global Cancer Observatory (GLOBOCAN) on 2018, gallbladder cancer ranks 22nd in global cancer incidence and 17th among the leading causes of cancer-related mortality worldwide.
Purpose: To describe the diagnostic approach and surgical management of a patient with suspected malignant gallbladder tumor.
Method: Descriptive analytic research used a case study approach involving a 51-year-old woman presented with a chief complaint of right upper abdominal pain that had persisted for three months prior to hospital admission. Clinical and diagnostic evaluations were performed using abdominal ultrasonography, multislice computed tomography (MSCT), and magnetic resonance imaging with Magnetic Resonance Cholangiopancreatography (MRI-MRCP) to establish the diagnosis and determine tumor staging.
Results: Radiological findings revealed a mass in the gallbladder suggestive of a malignant gallbladder tumor with a clinical stage of cT3N1M0. The patient subsequently underwent surgical intervention through an open laparotomy approach consisting of cholecystectomy combined with resection of tumor-invaded tissues or adjacent organs. Postoperatively, the patient’s condition was stable, and further oncological management with chemotherapy was planned as part of a comprehensive treatment strategy.
Conclusion: Gallbladder tumor at stage cT3N1M0 represents an aggressive malignancy that is often diagnosed at an advanced stage. A multimodal diagnostic approach and adequate surgical resection are essential in the management of this condition to improve patient survival outcomes.
Downloads
References
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 68(6), 394–424.
Bridgewater, J., Galle, P. R., Khan, S. A., Llovet, J. M., Park, J. W., Patel, T., Pawlik, T. M., & Gores, G. J. (2014). Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. Journal of Hepatology, 60(6), 1268–1289.
Goetze, T. O. (2015). Gallbladder carcinoma: Prognostic factors and therapeutic options. World Journal of Gastroenterology, 21(43), 12211–12217.
Grivennikov, S. I., Greten, F. R., & Karin, M. (2010). Immunity, inflammation, and cancer. Cell, 140(6), 883–899.
Hundal, R., & Shaffer, E. A. (2014). Gallbladder cancer: Epidemiology and outcome. Clinical Epidemiology, 6, 99–109.
Kim, S. J., Lee, J. M., Lee, J. Y., Kim, S. H., Han, J. K., Choi, B. I., & Choi, J. Y. (2008). Analysis of enhancement pattern of flat gallbladder wall thickening on MDCT to differentiate gallbladder cancer from cholecystitis. American Journal of Roentgenology, 191(3), 765-771.
Lazcano‐Ponce, E. C., Miquel, J. F., Muñoz, N., Herrero, R., Ferrecio, C., Wistuba, I. I.,& Nervi, F. (2001). Epidemiology and molecular pathology of gallbladder cancer. CA: a cancer journal for clinicians, 51(6), 349-364.
Ludwig, H., & Strasser, K. (2001). Symptomatology of anemia. Seminars in Oncology, 28(2 Suppl 8), 7–14.
Murphy, J. B. (1903). The diagnosis of gallstones. The American Journal of the Medical Sciences, 125(5), 825–846.
Randi, G., Franceschi, S., & La Vecchia, C. (2006). Gallbladder cancer worldwide: geographical distribution and risk factors. International journal of cancer, 118(7), 1591-1602.
Rawla, P., Sunkara, T., & Thandra, K. C. (2019). Epidemiology of gallbladder cancer. Clinical and Experimental Hepatology, 5(2), 93–102.
Roa, J. C., García, P., Kapoor, V. K., Maithel, S. K., Javle, M., & Koshiol, J. (2022). Publisher correction: gallbladder cancer. Nature Reviews Disease Primers, 8(1), 75.
Shindoh, J., De Aretxabala, X., Aloia, T. A., Roa, J. C., Roa, I., Zimmitti, G., & Vauthey, J. N. (2015). Tumor location is a strong predictor of tumor progression and survival in T2 gallbladder cancer: an international multicenter study. Annals of surgery, 261(4), 733-739.
Siegel, R. L., Miller, K. D., & Jemal, A. (2018). Cancer statistics, 2018. CA: a cancer journal for clinicians, 68(1), 7-30.
Siegel, R. L., Miller, K. D., Wagle, N. S., & Jemal, A. (2023). Cancer statistics, 2023. CA: A Cancer Journal for Clinicians, 73(1), 17–48.
Stinton, L. M., & Shaffer, E. A. (2012). Epidemiology of gallbladder disease: Cholelithiasis and cancer. Gut and Liver, 6(2), 172–187.
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 71(3), 209–249.
Valle, J. W., Kelley, R. K., Nervi, B., Oh, D. Y., & Zhu, A. X. (2021). Biliary tract cancer. The Lancet, 397(10272), 428–444.
Valle, J., Wasan, H., Palmer, D. H., Cunningham, D., Anthoney, A., Maraveyas, A., & Bridgewater, J. (2010). Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. New England Journal of Medicine, 362(14), 1273-1281.
Zhu, A. X., Hong, T. S., Hezel, A. F., & Kooby, D. A. (2010). Current management of gallbladder carcinoma. The Oncologist, 15(2), 168–181.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Muhammad Arfan, Samuel Sampetoding, Eva Miranda Fitri, Muhammad Lingga Primananda
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
